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Abstract
Smoking is the leading cause of preventable death worldwide. Accordingly, effort has been devoted to determining the
genetic variants that contribute to smoking risk. Genome-wide association studies have identified several variants in
nicotinic acetylcholine receptor genes that contribute to nicotine dependence risk. We previously undertook pooled
sequencing of the coding regions and flanking sequence of the CHRNA5, CHRNA3, CHRNB4, CHRNA6 and CHRNB3 genes and
found that rare missense variants at conserved residues in CHRNB4 are associated with reduced risk of nicotine dependence
among African Americans. We identified 10 low frequency (,5%) non-synonymous variants in CHRNB4 and investigated
functional effects by co-expression with normal a3 or a4 subunits in human embryonic kidney cells. Voltage-clamp was
used to obtain acetylcholine and nicotine concentration–response curves and qRT-PCR, western blots and cell-surface
ELISAs were performed to assess expression levels. These results were used to functionally weight genetic variants in a
gene-based association test. We find that there is a highly significant correlation between carrier status weighted by either
acetylcholine EC50 (b = 20.67, r2 = 0.017, P = 261024) or by response to low nicotine (b = 20.29, r2 = 0.02, P = 661025) when
variants are expressed with the a3 subunit. In contrast, there is no significant association when carrier status is unweighted
(b = 20.04, r2 = 0.0009, P = 0.54). These results highlight the value of functional analysis of variants and the advantages to
integrating such data into genetic studies. They also suggest that an increased sensitivity to low concentrations of nicotine
is protective from the risk of developing nicotine dependence.
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Variants in or near nicotinic acetylcholine receptor genes have
been found to be associated with nicotine related behavior in
humans. A non-synonymous change (rs16969968; a5 D398N) in
CHRNA5 is the most strongly associated single nucleotide
polymorphism (SNP) in several genome-wide association studies
(GWAS) of smoking quantity [5,6], with the N398 variant
associated with increased risk. Additionally, variants near
CHRNA5, that alter CHRNA5 mRNA expression in vivo, alter risk
for both nicotine and alcohol dependence [7,8]. A group of
common SNPs near the CHRNB3-CHRNA6 gene cluster also are
associated with cigarette consumption in a recent GWAS [5].
Sequencing of the neuronal nicotinic receptor genes in cohorts of
nicotine dependent cases and controls has also found associations
between variants in three nicotinic receptor genes, CHRNA3,
CHRNA4 and CHRNB4, with the risk for nicotine dependence
[9,10,11]. These findings indicate that the properties of nicotinic
receptor subunits are strongly associated with the risk of

Introduction
Nicotinic acetylcholine receptors (nAChRs) are pentameric
ligand-gated ion channels formed from numerous combinations of
receptor subunits, each encoded by a separate gene. Neuronal
nAChR a subunits are encoded by eight genes in mammals
(CHRNA2-A7, CHRNA9-10) and the b subunits by three genes
(CHRNB2-B4). The a7, a9 and a10 subunits can form functional
receptors without incorporating a b subunit, while a minimum of
two a and two b subunits (plus one additional subunit) are
required to form functional heteromeric receptors. Certain
combinations of receptor subunits are more common in the
central nervous system (CNS), and there is regional specificity with
regard to subtype expression in the mammalian CNS [1]. The
expression of the a3b4* subtype (the asterisk denotes any one of
multiple accessory subunits), for instance, is limited for the most
part to autonomic and sensory ganglia, medial habenula and the
interpeduncular nucleus (IPN), while a4b2* receptors can be
found almost ubiquitously throughout the brain [2,3,4].
PLOS ONE | www.plosone.org
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using Lipofectamine 2000 (Life Technologies, Carlsbad CA)
according to the manufacturer’s protocol incubated in a humidified atmosphere containing 5% CO2 at 37uC.

developing nicotine dependence, but do not provide insights into
the possible mechanisms for the association.
We have provided evidence that rare variants in CHRNB4
identified in a deep resequencing study of a cohort of nicotinedependent and control subjects were associated with reduced risk
of developing nicotine dependence [11]. However, this association
was based simply on the presence or absence of selected variants,
without considering the possible functional effects a variant might
have. In the present study we determine whether information from
in vitro tests of functional consequences of non-synonymous coding
variants can significantly improve the association between
genotype and phenotype. We report the functional impact of rare
variants in CHRNB4, and results that demonstrate that incorporating information on the functional consequences can improve
the association between genotype and the complex behavioral
phenotype of nicotine dependence. Furthermore, the results
suggest that an increased response to low concentrations of
nicotine may reduce the risk of developing nicotine dependence.

mRNA Expression
To measure CHRNB4 mRNA production HEK 293 cells were
transiently transfected with a negative control (empty pcDNA3), or
wild-type a3 plus wild-type or variant b4 constructs. After two
days of growth, RNA was extracted from cell lysates with an
RNeasy kit (Qiagen). Extracted RNA (10 ug) was then converted
to cDNA using the High Capacity cDNA Reverse Transcriptase
kit (Life Technologies). CHRNB4 mRNA expression was then
measured using SYBRgreen (Life Technologies, Carlsbad, CA)
using one primer spanning the boundary between exons 3 and 4
and another primer spanning the boundary between exons 4 and 5
to ensure only cDNA was amplified.

Western Blots
To measure b4 protein levels in transiently transfected HEK293
cells, we performed western blots on cell lysates using a poly-clonal
b4 antibody generously provided by Dr. Cecilia Gotti (CNR
Institute of Neuroscience, Pisa, Italy). After two days of growth,
each well of the 6-well plate was used to create a cell lysate. Cells
were lysed with 150 ml of lysis buffer (50 mM Tris (pH 6.8),
150 mM NaCl, 2 mM EDTA, 0.25% NP40, 1% TritonX). Total
protein concentration was then measured by the bicinchoninic
acid (BCA) method (Thermo Fisher Scientific, Waltham MA) for
each cell lysate. 20 mg of protein from each lysate was incubated at
95uC for 5 min in 16 Laemmli buffer (0.25 M Tris (pH 6.8), 8%
SDS, 40% glycerol, 0.01% bromophenol blue dye and 20% bmercaptoethanol). Denatured samples were loaded onto a 4–20%
Criterion (Bio-Rad, Hercules, CA) gel in TG-SDS buffer (0.01%
SDS, 25 mM Glycine, 2.5 mM Tris (pH 6.8)) and run at 125 V
for 90 min. Protein in the gel was transferred to a nitrocellulose
membrane in TG-SDS buffer containing 20% methanol overnight
at 4uC. Blots were incubated in TG-SDS containing 4% powdered
milk for 25 min at room temperature, then incubated at room
temperature with a primary b4 polyclonal antibody for 90 min.
The blots were then rinsed 36 with phosphate-buffered saline
(PBS; 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, and
1.4 mM KH2PO4, pH 7.3) containing 1% Triton-X for 5 min,
incubated with a horseradish peroxidase conjugated secondary
antibody (Thermo Fisher Scientific), washed 36 with PBS
containing 1% Triton-X for 5 min and finally incubated with
the horseradish peroxidase substrate 3, 3, 5, 5, 0-tetramethylbenzidine. Images were taken allowing for 5 min of exposure using a
Syngene western blot imager (Syngene, Frederick, MD).
For digestion with PNGase, 1 ml of 106 glycoprotein denaturing buffer was added to 20 mg of protein from each lysate and
incubated at 100uC for 10 min. Subsequently, 2 ml 106 G7
Reaction Buffer (NEB, Ipswich, MA), 2 ml 10% NP40 (NEB),
H2O and 2 ml PNGaseF (NEB) were then added to reach a total
reaction volume of 20 ml. This reaction was then incubated at
37uC for 1 h. Upon completion of the PNGase reaction, the
resultant solution was run on western blots as described above.

Materials and Methods
Ethics Statement
De-identified data from the Collaborative Genetic Study of
Nicotine Dependence (COGEND) were used. All participants in
COGEND provided written informed consent for genetic studies
and agreed to share their DNA and phenotypic information for
research purposes. The Washington University Human Research
Protection Office granted approval for data to be used for this
study.

Generation and Expression of Constructs
Full length coding sequences for the human nicotinic a3
(NP_000734.2) and b4 (NP_000741.1) subunits were kindly
provided by Dr. J. Lindstrom (University of Pennsylvania,
Philadelphia, PA). Subunits were sub-cloned into the pcDNA3
vector (Life Technologies, Grand Island NY). The FLAG epitope
[DYKDDDDK] was introduced into a4 between the 6 and 7
positions of the mature polypeptide using QuikChange (Stratagene, San Diego, CA). Mutations that produced the variants were
also introduced using the QuikChange kit. For each construct the
entire subunit coding region was sequenced to verify that only the
desired mutation had been introduced.

Cell Culture and Transfection
HEK 293 cells (American Tissue Culture Collection, Gaithersburg, MD) were maintained in a mixture of Dulbecco’s modified
Eagle’s medium (DMEM) and Ham’s F12 (1:1, also containing
2 mM L-glutamine and 15 mM HEPES), with 10% fetal bovine
serum (Hyclone, Logan, UT), penicillin (100 units/ml) and
streptomycin (100 ug/ml) in a humidified atmosphere containing
5% CO2 at 37uC. Cells were re-plated in the same medium the
day before transfection.
For physiological and cell surface ELISA studies, subunits were
transfected at a 1:1 mass ratio using Effectene (Qiagen, Valencia,
CA) according to the manufacturer’s instructions. Briefly, 3 mg of
cDNA per well of a 24-well dish was mixed with the Enhancer and
the Effectene Transfection Reagent. The cells were incubated with
the mix for 6 to 18 h. Electrophysiological experiments were
performed on either the second or third day after transfection,
while ELISAs were performed on the third day after transfection.
For mRNA expression and protein expression experiments, cells
were seeded into 6-well polylysine-coated plates and cultured in
DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM
L-glutamine, and penicillin/streptomycin. Cells were transfected
PLOS ONE | www.plosone.org

Cell-Surface ELISA
Surface ELISA assays were performed as described previously
[12]. Briefly, cells were plated in 24 well tissue culture plates at
about 100,000 cells/well. The next day cells were transfected as
described. In each experiment, a negative control (empty
pcDNA3) and a positive control (wild-type subunits) were
performed. Five wells were transfected with each subunit
combination in each experiment; 3 were used for ELISA and 2
2
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tained by applying pulses of different agonist concentration. The
data from a cell were analyzed by fitting with the Hill equation:
Y(X) = a(1/(1+(X/EC50)n)) where Y(X) is the response to a
concentration X, and the parameters a (maximal response),
EC50 (concentration giving half-maximal response) and n (Hill
coefficient) were determined by non-linear regression using
SigmaPlot (Systat Software, Chicago, IL). To combine data, the
relationship for each cell was scaled by the fit maximum. In some
cases, it was clear that high concentrations of agonist produced a
reduced response, likely due to open-channel block by the agonist
[14,15,16]. Accordingly, responses to high concentrations that
produced a lower response than responses to lower concentrations
were not included in the fit.
Concentration-response data for ACh and nicotine were
obtained on different cells, to minimize the duration of wholecell recording. Previous work has demonstrated that there can be
changes in the peak response and/or the desensitization properties
of neuronal nicotinic receptors over the time of whole-cell
recording [15,17]. Accordingly, each cell was tested with a high
concentration of ACh (usually 1 mM), and this value was used to
normalize the nicotine concentration-response relationship to the
overall averaged ACh concentration-response relationship for that
particular subunit combination. Similarly, some cells were tested
with single applications of a high concentration of ACh and a high
concentration of nicotine to obtain estimates for relative maximal
responses. In this case, the relative maximal response to nicotine
was normalized to both the mean concentration-response data for
nicotine and for ACh for that subunit combination.
Desensitization was estimated from the ratio of the current at
the end of the 4 sec pulse of agonist to the peak current during the
application. Studies of desensitization can be complicated by the
presence of additional receptor processes (such as channel block).
Accordingly, the measurements were performed using the
concentrations closest to the half-maximal concentration of agonist
to avoid channel block. Neuronal nicotinic receptors show
evidence for multiple, kinetically distinct, forms of desensitization
[15,17] that may exhibit both agonist and concentration
dependence in prevalence. Accordingly, our measurement provides a rough estimate of the rate of accumulation of desensitized
receptors. We did not examine recovery from desensitization. To
avoid over definition of the phenomenon, we will call this
measurement ‘‘sag’’ in the text.
The cells used for physiological studies all were selected on the
basis that they expressed receptors on the cell surface. Accordingly
the average maximal response to acetylcholine will not be
representative of the total cell population. Therefore, we adopted
the relative cell surface ELISA signal as the assay for numbers of
surface receptors for the different receptors expressed.

for a protein assay. For the ELISA assay, cells were rinsed in PBS
then blocked for 30 min at room temperature with 4% powdered
milk in PBS (milk-PBS). To detect a3 mAb 35 was used as primary
antibody (Sigma-Aldrich, St. Louis MO; diluted 1:400 in milkPBS) for 1 h at room temperature. Cells were then washed twice
with milk-PBS and incubated with anti-rat IgG peroxidaseconjugated goat antibodies (Sigma-Aldrich, 1:100 dilution in
milk/PBS) for 1 h. To detect FLAG-tagged a4, cells were
incubated with M2 antibody (Sigma-Aldrich, 2 mg/ml in milkPBS) as described and then incubated with sheep anti-mouse IgG
peroxidase-conjugated antibodies (Sigma-Aldrich; 1:100 dilution
in milk/PBS) for 1 h. Cells were washed with MPBS twice and
PBS twice, then assayed using the 1-Step Ultra TMB-ELISA kit
(Thermo Scientific). Absorbance was read at 405 nm using a
microplate reader (iMark, Bio-Rad, Hercules, CA). Total cell
protein was assayed from wells that had been maintained in milkPBS, then washed twice with PBS before assay by a BCA method.
For each experiment, the ELISA signal was obtained from
triplicate wells and the cell protein from duplicate wells.
The surface ELISA data were analyzed as follows. The machine
background was subtracted from each OD reading, then the OD
readings were divided by the protein for that subunit combination.
The normalized value for the negative control (pcDNA3) for that
experiment was then subtracted from all values. Finally, to control
for variation in expression between experiments, the subtracted
expression levels were normalized to the positive control (wildtype) value for that experiment. The final value gives an estimate
of the relative expression where a value of 1 indicates identical
expression to wild-type subunits.

Whole-cell Patch Clamp
Cells were plated in 35 mm tissue culture dishes, and
maintained and transfected as described. For recordings, cells
were rinsed with recording bath solution (140 mM NaCl, 5 mM
KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM glucose, and 10 mM
HEPES, pH 7.4) and cells expressing high levels of surface
receptors were identified by a bead-binding technique [13]. We
used mAb35 (Sigma-Aldrich) to identify a3 and mAb299 for a4
(Sigma-Aldrich). Antibody was adsorbed to immunobeads with a
covalently attached secondary antibody (Life Technologies). The
cells were incubated with a suspension of beads for 5 to 10 min
with gentle shaking, and cells expressing surface receptors were
identified from the presence of beads bound to the cell. This
greatly enhanced our ability to identify cells expressing measurable
numbers of receptors. The FLAG-tagged a4 subunit was not used
in physiological experiments.
Macroscopic currents were recorded using whole-cell voltage
clamp as described [13]. The pipette (intracellular) solution
contained 140 mM CsCl, 4 mM NaCl, 4 mM MgCl2, 0.5 mM
CaCl2, 5 mM EGTA, and 10 mM HEPES, pH 7.4. The drugs
were applied through the bath using an SF-77B fast perfusion
stepper system (Warner Instruments, Hamden, CT). Currents
were recorded using an Axopatch 200 amplifier (Molecular
Devices, Union City, CA). The cells were clamped at 260 mV
and all experiments were carried out at room temperature (20–
23uC). The current traces were low-pass filtered at 2 kHz and
digitized at 10 kHz. The analysis of whole-cell currents was
carried out using the pClamp 9.0 software package (Molecular
Devices).
The basic parameter measured was the peak response to a given
concentration of acetylcholine (ACh) or nicotine. Four sec pulses
of agonist were applied at intervals of 30 sec with continuous
application of bath solution between pulses to allow recovery from
desensitization. Concentration-response relationships were obPLOS ONE | www.plosone.org

Drugs, Data Presentation and Statistics
Unless otherwise noted all chemicals used were obtained from
Sigma-Aldrich.
Data are presented as mean 6 SE (number of observations). For
ELISA studies results from each experiment constituted one
observation; data were obtained in triplicate in each experiment.
For physiological results each cell constituted an observation (i.e.
EC50 or relative maximal response).
Parameters from fitting the Hill equation were excluded from
analysis if the standard error of any fit parameter for that cell (as
estimated by the fitting program) was 60% or more of the best
fitting value. Data from ELISA experiments were excluded if the
expression normalized to protein for the positive control (wild-type
subunits) did not differ from that for the negative control
3
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(pcDNA3) with a probability of less than 0.05 (two-tailed t-test),
indicating a failed transfection.
Basic statistical computations were made with Excel (Microsoft,
Redmond WA). ANOVA was performed using Stata (StataCorp,
College Station TX). Figures were prepared with SigmaPlot
(Systat Software, San Jose CA).
The homology model was made by threading the a3 and b4
subunits onto the C and D subunits respectively of the C. elegans
glutamate-activated Cl- channel X-ray crystal structure ([18]; PDB
3RHW) using the SWISS-MODEL web tool (http://swissmodel.
expasy.org/). Structures were visualized and displays generated
using Chimera 1.6.2 (http://www.cgl.ucsf.edu/chimera).

stratification, we calculated principal components (PCs) with
,3700 SNPs spread out across the genome [20] using EIGENSTRAT [21] and included the first two PCs as covariates in all
analyses. Carrier status was tested in a linear regression against
logCPD with age, sex, PC1 and PC2 as covariates. CPD values
were log transformed to approximate a normal distribution. To
analyze carrier status, individuals were coded as either 0 or 1
depending on whether they carried 0 or $1 missense variants at
any position in CHRNB4 [22]. To test the effect of variants
occurring at ‘‘conserved’’ residues (vertebrate phyloP score .2;
[23]), only individuals with such variants were coded as 1. To
analyze the function-weighted carrier status, individuals were
coded with the normalized parameter value for the tested
parameter (e.g. (ACh EC50, nicotine EC50, nicotine efficacy,
response to low nicotine and cell-surface expression) for the
particular variant the individual carried. These values were then
used as the predictor in a linear regression using age, sex, and the
first two principal components (PC1 and PC2) as covariates. As
described in the Results, data for variants occurring in only one
individual were included by weighting them by the parameter
value of the non-singleton variant or wild-type with the closest
parameter estimate.
Permutations for each of the significant parameters were
performed in R by randomly assigning one of the measured
parameter values to each of the variants without replacement. To
approximate the experimentally observed probability that the
association is significant we performed either 10,000 or 20,000
permutations. With these numbers of permutations a single more
significant result in the permutations would correspond to a
frequency of 0.0001 or 0.00005 that the experimental observation
would arise by chance.

Samples and Phenotype
DNA samples were collected as part of the Collaborative
Genetic Study of Nicotine Dependence (COGEND). All individuals were current or former smokers who had smoked at least 100
cigarettes in their lifetime and underwent a semi-structured
interview, which assessed smoking behavior, other substance use
and comorbid psychiatric conditions. The COGEND sample
includes 710 African Americans (461 nicotine dependent (ND)
cases and 249 smokers with no symptoms of dependence (controls).
Nicotine dependent cases have a Fagerström Test of Nicotine
Dependence (FTND) [19] score $4 while controls have an FTND
#1. In all cases lifetime maximum FTND score was used. One of
the questions within the FTND asks ‘‘How many cigarettes did
you smoke per day when you were smoking the most?’’ This value,
cigarettes per day (CPD), was used in our analyses assessing
whether functional characterization of alleles could improve
observed associations. A total of 352 African Americans were
sequenced in the original study. Follow up genotyping of SNPs
identified and validated in the sequenced individuals was done in
the remaining portion of the COGEND African American sample
(710 individuals total).
We focused our attention on the African-American population
for the following reasons. In our initial report [11] in which we
analyzed the association between carrier status for variants at four
conserved sites (T91I, G296S, T375I and M456V), there was a
significant association of carrier status with the control group for
the AA but not EA population. Further, the AA population
harbored 10 rare variants, while the EA population only had 4.
This suggested that the AA population was more suitable for the
analysis.
The Collaborative Genetic Study of Nicotine Dependence is a
collaborative research group and part of the National Institute on
Drug Abuse (NIDA) Genetics Consortium (http://www.ncbi.nlm.
nih.gov/projects/gap/cgi-bin/study.cgi?study_id = phs000092.v1.
p1). Subject collection was supported by NIH grant P01 CA89392
(PI - L Bierut) from the National Cancer Institute. Phenotypic and
genotypic data are stored in the NIDA Center for Genetic Studies
(NCGS) at http://zork.wustl.edu/under NIDA Contract
HHSN271200477451C (PIs J Tischfield and J Rice).

Results
Location of the Variants in a Homology Model of the
Receptor
The nicotinic receptor is a pentamer of highly homologous
subunits [24]. Each subunit comprises a relatively large aminoterminal extracellular domain that contains the binding site for
ACh, followed by a set of three closely spaced membrane-spanning
helical domains (TM1–TM3) that contribute regions forming the
ion channel. After these three domains is a cytoplasmic loop,
containing sites for phosphorylation and for association with
cytoplasmic proteins. The subunit ends with a 4th transmembrane
helix and a short extracellular carboxy-terminal domain. Most
variants are distributed in the N-terminal extracellular domain
(Figure 1). None of the variants is predicted to be at contact
regions between subunits, at which location they might affect
inter-subunit interactions. Similarly, the variants are not located in
the predicted ACh-binding regions, and none are located in the
2nd transmembrane domain that forms the major channel lining
segment and likely contains the channel gate. The cytoplasmic
domain is relatively poorly analyzed in terms of function and there
is no information on its structure, so little interpretation can be
made of variants in this region. In sum, there is no clear
relationship between the location of the variants and their
phenotype.

Ethics Statement
De-identified data from the Collaborative Genetic Study of
Nicotine Dependence (COGEND) were used. All participants in
COGEND provided written informed consent for genetic studies
and agreed to share their DNA and phenotypic information for
research purposes.

Selection of b4 Variants
The goal of this study was to determine whether functional
consequences of non-synonymous coding variants identified from
deep resequencing of the CHRNB4 locus could improve the
association between genotype and behavioral phenotype (cigarettes smoked per day; CPD). Accordingly, we generated

Association Analysis
Association analyses were performed in R (www.r-project.org)
using linear regression incorporating age and sex as covariates. In
order to ensure that associations were not affected by population
PLOS ONE | www.plosone.org
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cular nucleus, the medial habenula and the ventral tegmental area,
brain regions believed to be involved in addictive behavior, as well
as being the dominant form expressed in peripheral ganglia [2].
We also expressed b4 subunits with the a4 subunit, as this a
subunit is the most prevalent in the brain, and assembles with the
b4 subunit in several brain regions [1].
A total of 10 rare missense variants were identified in CHRNB4
and one rare missense variant was identified in the CHRNA3 as
part of the previous sequencing project. In this study we did not
examine the properties of the variant CHRNA3 subunit, so all
experiments were done with wild-type a3 and a4 subunits.
Analysis of the sequencing results reveals that several variants
show linkage disequilibrium and thus cosegregate non-randomly
in the population. Upon phasing of individual haplotypes, we
observed that everyone (17 individuals) carrying b4(R136W) also
carried b4(M467V) on the same allele, so we created an expression
construct both b4(R136W) and b4(M467V) in the same subunit
and used this double variant in functional studies rather than
b4(R136W). In addition, a subset of individuals carrying
b4(S140G) (32 out of 63) also carried b4(M467V) on the same
allele. Accordingly, we created expression constructs containing
both b4(S140G) and b4(M467V) and used this construct in studies,
as well as b4(S140G) and b4(M467V).

Subunit Expression: mRNA, Total Protein and Receptor
Surface Expression
We first measured mRNA expression levels produced by
plasmids containing each of the tested variants when expressed
together with wild-type CHRNA3 using qRT-PCR. We observed
no significant differences between the mRNA levels produced
from each variant-containing plasmid compared to wild-type
CHRNB4 containing plasmids (data not shown). These data
suggest that any observed differences in total or cell-surface
protein levels are not the result of altered initial mRNA levels.
Next, to determine if overall b4 protein, both intra-cellular and
cell-surface, was altered by the introduction of variants, we
performed western blots on total cell lysates from HEK 293 cells
transiently transfected with wild-type a3 and either wild-type or
mutant b4 containing plasmids. Analysis of the band intensity for
each mutant protein provided no evidence of altered total b4
expression for any of the variant plasmids (data not shown). The
S140G variant is predicted to abolish glycosylation at amino-acid
position 138. The S is the third amino acid in the consensus
glycosylation signal NXS, where X can be any amino acid. We
hypothesized that the absence of glycosylation at this site should
result in both faster migration on a western blot and low cellsurface protein expression. Both predictions were observed.
Furthermore, treatment with PNGase to remove all glycosylation
of wild-type b4 and b4(S140G) resulted in indistinguishable and
more rapid migration (data not shown).
To determine whether mutations in CHRNB4 alter the steadystate level of protein expressed on the cell-surface, we performed
cell-surface ELISAs on cultured HEK 293 cells two days after
transient transfection with constructs expressing either wild-type
b4 or variant b4 in conjunction with wild-type a3 or wild-type a4.
When the a3 or a4 subunits were transfected in the absence of a
b4 subunit the surface ELISA signal was indistinguishable from
that of cells transfected with empty vector (data not shown; twotailed t-test P.0.9).
Cell-surface expression was decreased for nearly all variants
tested (Tables 2 and 3). In addition, the correlation between
surface expression with a3 and a4 subunits was high (adjusted
r2 = 0.76, P = 0.01). The correlation suggests that the defect in
surface expression results from some inability of the b4 variants to

Figure 1. Locations of variants in a homology model of the
a3b4 receptor. The figure shows a homology model of the a3 and b4
subunits, generated using the GluCl crystal structure (see Methods). The
view is from the outside of the pentamer (see lower panel for cartoon),
and to simplify the image the 3 subunits on the far side of the channel
have been omitted. The backbones are shown in ribbon form (a3
yellow, b4 cyan). Locations of variants are shown as spheres colored as
follows: in b4(T91) pink, K57 purple, R136 dark blue, S140 light blue,
G296 orange, M467 dark green. A variant described in the a3 subunit
(a3(R37)) is shown in orange on the a3 subunit. The location of the
ACh-binding site is indicated by the red block arrow (the site is formed
at the a3–b4 interface). The brackets at the right indicate the
extracellular domain (ECD) and the transmembrane domain (TMD).
Note that the large intracellular loop is not present in the crystal
structure and so the b4(R349) and T375 residues are not shown.
doi:10.1371/journal.pone.0096753.g001

expression constructs containing the variants (see Table 1) and
examined the abilities of these variant subunits to be expressed, to
assemble into surface receptors and to function.
The b4 subunit can assemble with different a subunits to
produce functional receptors. We focused on the properties of
receptors containing the a3 and b4 subunits for several reasons.
First, the genes encoding these subunits are located proximally in
the human genome and have been shown previously to be highly
correlated in expression patterns across brain regions [25].
Second, one rare non-synonymous variant in CHRNA3 is in high
linkage disequilibrium with a rare non-synonymous variant in
CHRNB4, suggesting that there may be a functional relationship
between these variants in human populations (see below). Lastly,
this receptor subunit combination is expressed in the interpedun-
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Table 1. CHRNB4 missense variants examined.

Variant

PhyloP Score

Frequency (Number)

logCPD

b4

–

0.878 (1247)

0.0160.03

b4(T91I)

2.16

0.006 (9)

20.5760.3

b4(R136Q)

0.41

0.002 (3)

0.1360.07

b4(S140G)

2.27

0.022 (31)

0.0960.17

b4(T375I)

2.26

0.014 (20)

20.5960.18

b4(M467V)

1.58

0.041 (58)

0.1360.09

b4(M467V+R136W)

1.58

0.012 (17)

0.2960.27

b4(M467V+S140G)

2.27

0.023 (32)

20.1160.13

b4(K57E)

1.16

0.001 (1)

0.31

b4(G296S)

5.69

0.001 (1)

21.08

b4(R349C)

1.96

0.001 (1)

0.57

The first column shows variants in b4. The second column gives the PhyloP score for the variant. As discussed in Results, some alleles carried two variants (e.g. M467V+
R136W). For alleles carrying two variants, the PhyloP score is the greater of the two separate variants. The column headed Frequency gives the frequency of the variant
(number of chromosomes carrying the variant). The fourth column gives the measure of the behavioral phenotype used, the logarithm of the corrected cigarettes per
day (see Methods; values given as mean 6 SE). In the functionally weighted associations, singletons (bottom 3 rows) were weighted by the parameter value of the nonsingleton variant or wild-type with the nearest parameter value to that of the singleton variant (Tables 2 and 3).
doi:10.1371/journal.pone.0096753.t001

traces in Figure 2). Channel block was not studied further, as the
physiologically relevant concentrations are either lower or much
more transient.
The results are summarized in Figure 3, displayed as the value
for a variant-containing receptor relative to that for wild-type.
This emphasizes the consequences on function for the variants.
Measured data are presented in Tables 2 and 3.
We obtained concentration-response relationships for activation
by ACh and nicotine. Graphs of typical relationships are shown in
Figure 2 for a3b4 receptors. We estimated the potency of ACh
and nicotine from the concentrations producing half-maximal
activation (EC50), and results are summarized in Figure 3 and
Tables 2 and 3. Few of the variants resulted in significant changes
in the EC50 values for ACh (1 of 19 combinations) or nicotine (3 of
19).
The magnitude of the current elicited by a maximally effective
concentration of agonist gives a measure of the efficacy of the
agonist (that is, the maximal ability of the agonist to activate the
receptor). We do not know this value in absolute terms, for
example from single-channel studies that would directly measure
the probability a channel is open. However, we can estimate the
relative efficacy of nicotine compared to ACh from a ratio of the
estimated maximal responses from a cell tested with both agonists.
None of the combinations tested resulted in a significant change.
We obtained an estimate of the overall accumulation of
receptors in non-responsive states from the amount of decrement
(‘‘sag’’) from the peak response to the end of a 4 sec application of
agonist. As discussed in Methods, we used responses elicited by an
,EC50 concentration of agonist, to avoid possible complications
due to channel block by high concentrations. A value of 1 for sag
indicates that there was no decline in response, while a value of 0
indicates that the response declined completely to baseline. Most
variants showed no significant difference from wild-type in sag.
The b4(R136Q) variant showed greatly increased sag in the
presence of either ACh or nicotine, but only when expressed with
the a4 subunit.
Finally, we estimated the response to a low concentration of
nicotine, as a fraction of the maximal response to ACh. The brain
concentration of nicotine for a smoker is estimated to reach 100 to
1000 nM [27]. Receptors containing the a3 subunit did not

fold or traffic appropriately, rather than a specific defect in the
ability to interact with a particular a subunit. Further experiments
will be required to determine which mechanism(s) is more likely to
explain the reduced surface expression for each variant (e.g.
reduced assembly into pentamers, reduced forward trafficking to
the plasma membrane or enhanced removal from the plasma
membrane). An elegant study of a homologous mutation in the
mouse b4 subunit (b4(R348C); [26]) reported that the presence of
the variant reduced surface expression in cultured neurons by 2- to
3-fold (comparable to the 3- to 4-fold reduction in Tables 2 and 3)
largely by reducing forward trafficking from the endoplasmic
reticulum to the plasma membrane.

Physiological and Pharmacological Studies of Variant
Containing Receptors
To test the electrophysiological properties, receptors containing
wild-type and variant b4 subunits were co-expressed with a
subunits in HEK 293 cells. Whole-cell voltage-clamp experiments
were performed to examine the basic functional properties of
receptors containing variant subunits. Cells were selected using a
bead-binding assay (see Methods) to increase our chance of
obtaining measurable responses. To estimate the potency of ACh
and nicotine we determined the concentration that produced a
half-maximal response (EC50). A smaller EC50 value corresponds
to a higher potency. To measure the relative efficacy of nicotine
we determined the relative maximal response of a cell to nicotine
compared to the maximal response to ACh. We also measured the
relative response at the end of a 4 sec application of agonist,
compared to the peak, to estimate the overall accumulation of
receptors in a non-responsive (‘‘desensitized’’) state. Finally, we
measured the relative response to a low concentration of nicotine
(1 mM for a3-containing receptors and 0.3 mM for a4-containing
receptors) to estimate the response to a more pharmacologicallyrelevant concentration of nicotine.
Figure 2 shows typical physiological data and resulting
concentration-response relationships. Agonist-induced open-channel block is present at the highest concentrations of agonist, as
indicated by the rapid decline in response and the pronounced
‘‘rebound’’ response when agonist is suddenly removed (see red
PLOS ONE | www.plosone.org
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20.0660.14 (6)***

(20.04)

0.9760.29 (4) NS

(1.00)

0.2460.05 (7)***

(0.17)

b4(K57E)

(K57E)

b4(G296S)

(G296S)

b4(R349C)

(R349C)

(121)

101623 (5) NS

(54)

57638 (2) NS

(121)

110623 (5) NS

163637 (12) NS

5467 (16) NS

124620 (12) NS

127629 (6) NS

(25)

2666 (4) NS

(18)

1963 (6) NS

(56)

62611 (9)**

1863 (7) NS

3065 (17) NS

4466 (11) NS

33612 (7) NS

4864 (18)*

56610 (5)*

2566 (8) NS

2264 (9)

Nic EC50 (mM)

(0.77)

0.7960.07 (10) NS

(0.74)

0.7460.05 (6) NS

(0.77)

0.7960.03 (18) NS

0.6360.06 (7) NS

0.6160.02 (17) NS

0.6060.04 (11) NS

0.8160.04 (17) NS

0.7460.03 (18) NS

0.6960.05 (5) NS

0.7760.04 (15) NS

0.7360.03 (17)

Nicotine efficacy

(0.008)

0.00760.005 (4) NS

(0.02)

0.02060.009 (5) NS

(0.002)

0.00060.000 (9) NS

0.01360.003 (7) NS

0.01260.004 (17) NS

0.00860.004 (10) NS

0.03260.010 (7) NS

0.00260.001 (13) NS

0.01160.003 (5) NS

0.02060.006 (8) NS

0.01160.003 (9)

Response to 1 mM
Nicotine

(0.75)

0.7460.04 (10) NS

(0.90)

0.9460.03 (4) NS

(0.86)

0.8460.04 (4) NS

0.9060.03 (12) NS

0.8860.03 (14) NS

0.8760.04 (13) NS

0.8460.03 (14) NS

0.7560.05 (12) NS

0.8860.02 (7) NS

0.8260.03 (13) NS

0.8660.02 (22)

‘‘Sag’’ to ACh

(0.87)

0.8760.03 (9) NS

(1.00)

0.9860.01 (6) NS

(0.82)

0.8360.03 (9) NS

1.0060.01 (5) NS

0.8660.05 (17) NS

0.8760.05 (15) NS

0.9160.02 (10) NS

0.9360.03 (15) NS

0.8260.05 (6) NS

0.8560.02 (11) NS

0.8660.02 (19)

‘‘Sag’’ to nicotine

The first column shows the variant expressed. The remaining columns give the mean 6 SE value for parameters, derived from (N) measurements. The values for singletons (variants occurring in a single individual) are shown below
the empty row. In the functional weighting analysis these variants were grouped with the variant (or wild-type) parameter closest to the measured one (see Results); the values used are shown as bold font and in parentheses
immediately below the measured parameter. Receptors containing a3 and b4(K57E) showed no response to 1 mM nicotine. For the variants, the notations give the significance of the difference to the wild-type value (one way
ANOVA with Dunnett’s correction; NS P.0.05, *P,0.05, **P,0.01, ***P,0.001).
doi:10.1371/journal.pone.0096753.t002

0.6160.02 (2) NS

0.1760.02 (2)***

0.7360.22 (7)*

b4(M467V+R136W)

227677 (10) NS

0.4060.08 (5)***

b4(T375I)

b4(M467V)

b4(M467V+S140G)

121620 (12) NS

0.1660.16 (8)***

20.0460.05 (12)***

b4(R136Q)

b4(S140G)

146634 (20)
246651 (7) NS

1.0060.00 (60)

0.2760.06 (5)***

b4

ACh EC50 (mM)

Surface expression

b4(T91I)

Variant

Table 2. Functional parameters for variants expressed with the a3 subunit.
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2.2660.27 (6)***

(1.00)

0.1460.07 (4)***

(0.31)

b4(G296S)

(G296S)

b4(R349C)

(R349C)

(5.97)

6.3160.92 (7) NS

nd

(8.24)

7.6361.85 (4) NS

12.561.7 (6) NS

4.4961.15 (7) NS

8.2460.75 (13) NS

5.9761.42 (5) NS

(1.40)

1.3660.04 (7) NS

nd

(1.14)

0.7560.07 (9) NS

1.5660.24 (5) NS

2.0560.24 (6) NS

1.4060.11 (13) NS

1.1460.25 (7) NS

2.7560.27 (13)**

2.0160.31 (5) NS

1.6660.18 (8) NS

1.4860.17 (14)

Nic EC50 (mM)

(1.01)

1.0160.04 (7) NS

nd

(1.00)

0.9960.10 (9) NS

0.8860.07 (5) NS

1.0860.04 (6) NS

1.0760.06 (13) NS

1.0160.16 (7) NS

0.9660.05 (13) NS

1.0660.08 (5) NS

1.1860.08 (8) NS

1.0060.03 (14)

Nicotine efficacy

(0.059)

0.06360.008 (7) NS

nd

(0.186)

0.21860.031 (9)***

0.03560.013 (5) NS

0.07760.015 (6) NS

0.04460.006 (13) NS

0.18660.036 (7)***

0.02260.003 (13) NS

0.12260.019 (5) NS

0.09260.011 (8) NS

0.05960.012 (14)

Response to 0.3 mM
Nicotine

(0.90),

0.8860.02 (7) NS

nd

(0.95)

0.9360.01 (5) NS

0.9060.03 (6) NS

0.9560.03 (7) NS

0.8560.02 (18) NS

0.7660.04 (12)**

0.7660.04 (13)**

0.2660.06 (5)***

0.9560.02 (12) NS

0.9060.02 (20)

‘‘Sag’’ to ACh

(0.93)

0.9960.02 (7) NS

nd

(0.89)

0.8460.03 (11) NS

0.7960.10 (4) NS

0.9160.01 (6) NS

0.9260.02 (15) NS

0.9060.02 (11) NS

0.8960.02 (13) NS

0.3260.02 (4)***

0.9360.01 (12) NS

0.9160.03 (18)

‘‘Sag’’ to nicotine

The Table is presented in the same fashion as Table 2. For the variants, the notations give the significance of the difference to the wild-type value (one way ANOVA with Dunnett’s correction; NS P.0.05, *P,0.05, **P,0.01, ***P,
0.001, nd: not done).
doi:10.1371/journal.pone.0096753.t003

(20.13)

(K57E)

nd

b4(M467V+R136W)

nd

0.6060.24 (4)*

0.0360.03 (3)***

0.6860.04 (2) NS

b4(T375I)

b4(M467V)

b4(M467V+S140G)

8.6860.93 (7) NS

20.1360.22 (2)***

b4(S140G)

b4(K57E)

16.762.1 (14)**

0.8860.25 (3) NS

b4(R136Q)

13.362.4 (8) NS

9.3661.35 (14)

1.0060.00 (24)

0.3160.05 (2)**

b4(T91I)

ACh EC50 (mM)

b4

Surface expression

Variant

Table 3. Functional parameters for variants expressed with the a4 subunit.
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The responses to the highest concentrations are shown in red, to
emphasize the increased decline in response during the application and
the rebound current when agonist is removed. This pattern is
consistent with open-channel block by high concentrations of agonist.
doi:10.1371/journal.pone.0096753.g002

reliably respond to nicotine concentrations less than 1 mM, while
those containing the a4 subunit would respond reliably to 0.3 mM
nicotine. Accordingly responses to these concentrations were used
to estimate the relative response to a low concentration of nicotine.
Few of the variants resulted in significant changes in this
parameter (2 of 19 combinations).
In addition, we tested for correlations between parameters (e.g.
ACh EC50 and nicotine EC50). Our motivation was to determine
whether there were indications that variants had similar effects on
functional responses to both ACh and nicotine (possibly suggesting
an agonist-independent effect on activation) or on functional
responses when expressed with the two a subunits. We did not
correct the results for multiple comparisons (a total of 66). There
was a significant association between response to low nicotine
when expressed with an a3 subunit and response to low nicotine
when expressed with an a4 subunit (r2 = 0.90; P = 0.001) and
between the amount of sag when expressed with a3 and a4
(r2 = 0.87, P = 0.002). Overall, the functional effects of the variants
did not fall into a simple pattern, such as both ACh and nicotine
having reduced potency (increased EC50) when a variant is
expressed with a given a subunit, nor a pattern in which similar
effects occurred when a variant is expressed with different a
subunits.

Association Analyses
To determine if incorporation of results from our functional
analyses of all variants known to exist in our study population
could be used to improve power to detect an association between
nicotine related behaviors and variants in CHRNB4, we created a
genotype model weighted by the functional effects of each of the
variants. We used parameters estimated for each variant for
responses to nicotine and ACh as well as cell-surface protein level
to create quantitative measures of receptor function that we could
assign to each individual based on the alleles they harbor.
In order to compare our findings to conventional gene-based
association methods, we first performed an analysis simply using
carrier status at any non-synonymous site in CHRNB4 as the
predictor variable in a linear regression with log transformed
lifetime maximum number of cigarettes smoked per day (logCPD)
as the response variable and including age and sex as covariates.
Using all missense variants, there is no significant association
between carrier status at CHRNB4 and logCPD (b = 20.04,
p = 0.54, r2 = 0.0009) (Table 4). We have previously shown ([11])
that there is a significant association between carrier status of 4
variants (b4(T91I), b4(G296S), b4(T375I) and b4(M456V), each of
these variants has a vertebrate phyloP score .2) and control
phenotype (defined by FTND of , = 1). Accordingly, we selected
only the subset of missense variants that occurred at genomic
positions with an indication of cross-species conservation (defined
by vertebrate phyloP scores .2; Table 1). This reduced the
number of variants from 10 to 5. We observed a significant
association between carrying at least one missense variant at a
conserved site in CHRNB4 and logCPD (b = 20.24, P = 0.01,
r2 = 0.01) (Table 4). These observations provide a baseline for
determining whether including experimental data on function
improves the association of genotype with phenotype.
To perform parameter-weighted analyses of these data, we first
had to decide which parameters to use for individuals harboring
multiple variants. As mentioned, we observed that all individuals

Figure 2. Activation of receptors containing a3 and wild-type
b4 subunits. Panel A shows responses of a cell to various
concentrations of ACh and Panel B shows the response of a different
cell to various concentrations of nicotine (applications lasted 4 sec). In
Panel B the horizontal dashed line indicates the response of this cell to
1 mM ACh, to estimate the maximal response. The response to the
highest concentration of nicotine is clearly less than that to ACh,
indicating that the relative efficacy of nicotine is less than that of ACh.
Panel C shows the average normalized concentration effect curves for
a3b4 receptors (both curves normalized to the maximal response for
ACh). The symbols show mean 6 SE. The curves show the predictions
of the Hill equation (see Methods): Y(X) = a(1/(1+(X/EC50)n)) where a is
the maximal response, X is the concentration of agonist, n is the Hill
coefficient and EC50 is the concentration producing a half-maximal
effect. The curves were generated with the overall mean parameters; for
ACh EC50 146634 mM and Hill coefficient 1.0760.06 (20 cells), and for
nicotine EC50 2264 mM and Hill coefficient 1.1760.07 (9 cells). The
maximal response to nicotine relative to the maximal response to ACh
(the relative efficacy for nicotine) is 0.7360.03 (17 cells). The baseline
holding current before application has been subtracted from all traces.
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Figure 3. Consequences of variants for receptor properties. Each panel shows a cumulative distribution for the mean parameter values for
receptors with different b4 variants. The left graph in each pair shows data for receptors containing the a3 subunit, and the right graph data for
receptors containing the a4 subunit. The parameter values have been normalized to the value for wild-type b4 subunits to emphasize the relative
functional changes (the actual data are shown in Tables 2 and 3). Data for receptors containing wild-type b4 are shown by plus signs, for b4 variants
that have PhyloP scores less than 2 (‘‘nonconserved’’) by blue filled circles and for those with scores = .2 (‘‘conserved’’) by green filled inverted
triangles. Hollow symbols show values for variants occurring in only single individuals; these values were not used in the association analyses (see
Results). The vertical dashed line shows a relative value of 1 (equal to wild-type). The dashed curves show the cumulative normal distribution
predicted by the mean and standard deviation of the data excluding singletons.
doi:10.1371/journal.pone.0096753.g003

harboring b4(R136W) also harbored b4(M467V) on the same
allele and that all individuals harboring both b4(S140G) and
b4(M467V) harbored these variants on the same allele. As a result,
we used parameters estimated from constructs harboring both
variants. Every individual (a total of 9 in this population) carrying
b4(T91I) also carried a3(R37H). However, we had elected to study
properties of receptors with wild-type a subunits, and individuals
with a3(R37H) also carried a wild-type a3 allele. We found (data
not shown) that receptors containing the a3(R37H) variant
expressed poorly on the cell surface and so it is likely that most
functional receptors in the brain would contain wild-type a3
subunits. Finally, variants that occurred in only one individual
were grouped with the non-singleton variant or wild-type with the
nearest parameter estimate because values for the average CPD
for singleton variants would be poorly estimated due to sample size
(see Tables 2 and 3 for values used). We then weighted each
variant genotype by the value for each of the estimated functional
parameters. The results of the association analysis are summarized
in Table 4. We find that weighting by ACh EC50 for variants
expressed with a3 (b = 20.67, r2 = 0.017, P = 461024) or by
relative response to low nicotine when expressed with either a3
(b = 20.29, r2 = 0.021, P = 661025) or a4 (b = 20.25, r2 = 0.016,
P = 461024) explained more phenotypic variance and produced a

PLOS ONE | www.plosone.org

significant association. The results of this weighting procedure for
these significant parameters can be seen in Figure 4.
It is interesting to consider why selecting variants based on
PhyloP score improved the association, in the absence of any
functional weighting. A possible explanation is suggested by
considering Figure 3. It can be seen that the effects of variants at
conserved locations (vertebrate PhyloP score .2) are concentrated
at the right hand side of the distributions for the data for response
to low nicotine (expressed with either a3 or a4) and for the ACh
EC50 (expressed with a3). These parameters are the ones that
resulted in significant improvement in the association when
functional weighting was used, and the functionally-weighted
association indicated that large values were protective. We then
examined correlations between parameters and PhyloP score for
all variants examined including singletons, using 2 metrics. The
first was the relative parameter value, and the second was the
absolute value of the logarithm of the relative parameter value.
The second metric was used as a measure of effect size irrespective
of direction, since relative values of 2-fold and one half would
receive equal treatment. With a total of 32 regressions, 3 showed a
P value less than 0.05: for ‘‘sag’’ for variants expressed with a3 the
linear parameters had P = 0.015 and the logarithmic parameters
P = 0.037, while for the ACh EC50 for variants expressed with a3
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Table 4. Results from parameter-weighted linear regression.

Weighting

r2

b

P-value

Any Variant, unweighted

20.04

0.0009

0.54

Variants with PhyloP.2

20.22

0.008

0.01

a3 Low Nicotine

20.29

0.021

661025

a4 Low Nicotine

20.25

0.016

461024

a3 ACh EC50

20.67

0.017

261024

Functional weighting

a4 ACh EC50

20.12

0.0004

0.41

a3 Nicotine EC50

0.05

0.0003

0.26

a4 Nicotine EC50

0.22

0.001

0.16

a3 Nicotine Efficacy

20.89

0.001

0.18

a4 Nicotine Efficacy

20.11

0.001

0.86

a3 Cell-Surface Expression

0.053

0.0002

0.54

a4 Cell-Surface Expression

0.056

0.001

0.59

a3 ACh ‘‘sag’’

0.27

0.0001

0.80

a4 ACh ‘‘sag’’

0.25

0.0003

0.60

a3 Nicotine ‘‘sag’’

20.93

0.002

0.21

a4 Nicotine ‘‘sag’’

0.08

.0001

0.89

The first column gives the weighting applied to the variant status. For each analysis, the phenotype used was log transformed CPD residuals (see Methods and mean
values shown in Table 1). Carrier status was first used as an unweighted predictor of CPD, then carrier status at a subset of variant positions (those with phyloP scores .
2; see Table 1). Lastly, carrier status was weighted by each of the listed parameters and used in the linear regression as the predictor. Variants of b4 were expressed with
the a subunit shown, and parameter values used are in Tables 2 and 3). The columns give the slope of the relationship (b, where a negative value indicates that reduced
CPD was associated with a larger value of the parameter), the adjusted r2 value and the probability that the slope is equal to zero. Associations were performed using
linear regression in R.
doi:10.1371/journal.pone.0096753.t004

the logarithmic parameters had P = 0.039 (the linear parameters
had P = 0.5) (results not corrected for multiple comparisons).
These observations indicate that the PhyloP score is not a strong
predictor of functional effect. Our observation that weighting
variants based on occurrence at a conserved position improved
association appears to be happenstance, and based on the
particular distribution of functional effects with respect to PhyloP
scores.
In order to determine if the association we observed between
CPD and CHRNB4 variants weighted by functional consequence
could be due to chance, we performed permutation tests. For each
of the significant parameters (response to low nicotine when
expressed with a3, response to low nicotine when expressed with
a4 or ACh EC50 when expressed with a3) we randomly assigned
parameter values from the set of measured values we obtained to
each of the variants without replacement and performed 10,000 or
20,000 permutations. The number of permutations performed was
selected to provide a reasonable chance of obtaining a probability
comparable to the experimentally observed one - for example with
experimental P = 661025, observing one more significant association in 20,000 permutations would give an estimate of 1/20,000
(561025). In the case of response to low nicotine when expressed
with a3 (association P of 661025) none of 20,000 permutations
had a lower P value, indicating that the association is likely
significant at P,561025. For ACh EC50 when expressed with a3
(P = 261024) 48 of 10,000 had a lower P value, suggesting the
association is likely significant at P,561023. However, for
response to low nicotine when expressed with a4 (P = 461024)
960 of 10,000 permutations had a lower P value, suggesting that
this association could readily arise by chance.
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Discussion
Common variants only account for a small fraction of the risk of
developing nicotine dependence, suggesting that a major portion
of the genetic contribution to the risk of developing nicotine
dependence might result from many rare variants. We previously
showed [11] that selected rare variants at 4 conserved residues in
CHRNB4 are associated with reduced nicotine dependence risk.
We extended this analysis by including all variants and incorporating the experimentally determined functional consequences of
the incorporation of subunits harboring rare variants. The
mechanism underlying an association, however, can be unclear.
The complexity of the effects of nicotine in the brain, its
metabolism and the neuronal networks that lead to addiction
make prediction of the relationship between genetic variants and
behavior difficult. Even in the specific case of variants in the
neuronal nicotinic receptors it is difficult to reach definitive
conclusions regarding the role of variants in these genes in vivo in
the absence of knowledge of the functional effects. This is largely
due to two factors: (1) the role of neuronal nicotinic receptors in
the brain is not well understood and (2) these receptor subunits
combine in many different combinations, forming sub-types
expressed in various patterns with indeterminate functional
redundancy. Even when functional effects are identified, it can
be difficult to directly connect the functional change to the
behavioral phenotype and, at present, it is not possible to a priori
associate a receptor functional phenotype with the risk of
developing nicotine dependence. We have taken a different
approach, which is to measure a number of basic functional
properties and to determine which properties improve the
association between genotype and phenotype, with the idea that
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Figure 4. Correlation between Functional Parameters and CPD. The panels show the distribution of log(CPD) after correcting for age and sex,
plotted against the relative parameter values for the 3 functional parameters that produced a significant association. The dashed red line is the
estimated linear relationship. Horizontal lines mark the mean CPD residuals of carriers of each variant. Linear regression was performed in R. Singleton
variants were included by weighting them by the parameter of the non-singleton variant (or wild-type) with the closest parameter estimate (see
Results and Tables 2 and 3).
doi:10.1371/journal.pone.0096753.g004

this will provide insights into possible underlying functional
changes.
Accordingly, we characterized the functional consequences of
rare variants in the CHRNB4 gene observed from sequencing a
PLOS ONE | www.plosone.org

cohort of nicotine dependent individuals and non-dependent
smoking controls. These parameters were then used to weight
variants in a gene-based association test to test the hypothesis that
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However, these experimental advantages come with a significant
simplification of the situation in the brain. In particular all neuronspecific effects on assembly, trafficking or post-translational
modification are lost in this model. The use of single a and b4
subunits does not recapitulate the natural competition among
subunits for incorporation into receptors in neurons, which
typically express multiple subunits. Our approach also presumes
that the effects we see when CHRNB4 variants are expressed with
the a3 or a4 subunits are the most informative of the possible
subunit combinations. These a subunits were chosen based on
prevalence and possible relevance to nicotine behavioral phenotype, but it may be that other combinations are more directly
involved in nicotine dependence. Indeed, the lack of correlations
between physiological consequences when variants were expressed
with the a3 compared to a4 subunits suggests that the variants
may have different effects in receptors of different composition.
Finally, only a limited number of functional parameters were
assayed, and it may be that the most significant attribute was
missed.
A further caveat to our interpretations arises from the
observation that ab nicotinic receptors can assemble in 2 subunit
stoichiometries - 2a to 3b or 3a to 2b - with different properties.
Studies of a3b4 and a4b4 receptors indicate that both of these
subunit combinations can assemble in either stoichiometry
[29,30]. However, we used only a single subunit stoichiometry
in our transfections. This caveat is given particular significance by
the recent report that rare variants in the a4 subunit can result in
changes in subunit stoichiometry for a4b2 receptors [31]. It is
possible that similar effects might occur with the b4 variants we
tested, and thereby produce some of the alterations in functional
properties.
Few studies have been made of the functional properties of
receptors containing variant b4 subunits. In one, 4 variants were
expressed in Xenopus oocytes with the a4 subunit [32]. The authors
tested the T91I, R136W, S140G and M467V variants, and found
relatively small changes in the EC50 for ACh of a similar
magnitude and direction to our observations. The second study
examined the properties of the R349C variant, expressed in
GH4C1 cells [33]. In this study, a relatively large increase in the
EC50 for ACh was found when the variant was expressed with the
a3 subunit (3.2-fold) in comparison to our modest decrease (to 0.7fold). When expressed with the a4 subunit, the variant increased
the EC50 for ACh by 3.3-fold (compared to a decrease to 0.7 in
our results) and that for nicotine by almost 17-fold (compared to a
decrease to 0.9). However, there did not appear to be any change
in nicotine relative efficacy (as we also found). We do not have an
explanation for the difference in results.
Recent work suggests that the a3b4* subtype of nicotinic
receptors may contribute significantly to nicotine related behaviors
by activating the habenulo-interpeduncular pathway [25,34,35].
Additionally, a recent association study of smoking cessation has
shown that variants in CHRNB4 may decrease craving and
withdrawal symptoms [36]. Our results are consistent with these
reports in indicating a role for the b4 subunit in smoking behavior.
The single variant with the strongest association with nicotine
dependence is a nonsynonymous coding variant in the a5 subunit,
which results in the replacement of aspartate 398 with asparagine
[6]. This variant has been found to enhance desensitization [37]
and reduce the maximal response to agonists [38], and is
associated with an increased risk of nicotine dependence. A very
recent study found that three rare variants in the major
cytoplasmic loop of the a4 subunit affected several properties of
a4-b2 receptors, including enhancing the proportion of receptors
that showed a high sensitivity to ACh [31]. These variants are

relevant parameters will improve the observed association at this
locus.
The majority of variants significantly reduced cell-surface
protein expression. Despite this, cell-surface expression was not
significantly associated with CPD in this dataset. This is, perhaps,
expected as mice lacking the b4 subunit only show alterations in
nicotine withdrawal symptoms and decreased adverse effects at
high nicotine doses compared to wild-type, suggesting that even
large effects on protein level may have small effects on behavior
[28]. The overall consequences in the brain of reduced surface
expression will depend on several factors, as the variant occurs in
the presence of a wild-type allele. The effects will likely depend on
the exact mechanism underlying the reduction, which our data do
not address, and the overall metabolism of the receptors and
subunits. If subunit maturation of the variant subunit is reduced so
that it does not even assemble to form a pentameric receptor, then
it appears likely that the majority of surface receptors will contain
the wild-type allele, albeit at a possibly reduced level from a
homozygous wild-type individual. The amount of reduction will
depend on whether the b4 subunit is normally in excess in
comparison to other subunits. If, on the other hand, the variant
subunit assembles but reduces forward trafficking (or increases
retrieval from the plasma membrane) of pentamers then it seems
likely that some fraction of surface receptors will contain a variant
subunit because the variant will be incorporated into pentamers
and susceptible to trafficking to the surface. The proportion will
depend on the stoichiometry of the assembled pentamers and on
the effects on trafficking resulting from incorporation of 1, 2 or 3
variant subunits. However, likely only a minority of receptors
would contain only wild-type subunits. Given this uncertainty, the
lack of major effects of gene knockout in mice, and the lack of
improved association when surface expression was used as a single
functional weighting parameter, we did not pursue multiple factor
association analysis incorporating data on surface expression.
Most variants had relatively small effects on the aspects of
receptor function we measured. However, even in the face of these
small individual effects we found that 3 parameters provided large
increases in the significance of the association between genotype
and phenotype. Our results indicate that among the parameters
estimated for each of the CHRNB4 variants, response to low
concentrations of nicotine and ACh EC50 were able to improve
the observed association between rare variants in CHRNB4 and
CPD. In each case the association indicated that large values of the
parameter is protective - a larger response to low nicotine or a less
potent effect of ACh. This suggests that overall an enhanced
response to concentrations of nicotine that may be reached in the
brain of a smoker may be a protective factor. The other
parameters did not result in significant improvements in association, although the overall trends (Table 4) were that decreased
nicotine EC50, increased nicotine efficacy or increased ACh EC50
were associated with reduced CPD. Each of these trends would be
associated with a larger relative response to low nicotine,
everything else being equal.
There are some experimental factors in our approach that affect
the interpretation of these results. First, all experiments were
performed in HEK 293 cells. This was done for several reasons.
The major one is that it allowed us to define the subunit
composition of the expressed receptors, and hence to examine
consequences of expression of variants with different a subunits. A
second reason is that it provided a robust expression system that
would be less susceptible to variability due to phenotypic diversity,
including endogenous subunit expression, in neuronal cells.
Finally, HEK 293 cells are widely used and therefore are suitable
to replication or extension of our work by other laboratories.
PLOS ONE | www.plosone.org
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found more often in control than nicotine dependent individuals
[10]. Finally, studies of a variant in the a4 subunit in mice have
found that it increases the sensitivity to nicotinic activation and
also reduces the severity of responses to nicotine [39]. These
observations have led to the suggestion that reduced sensitivity to
activation by agonists results in increased risk for developing
nicotine dependence and that, conversely, increased sensitivity
reduces the risk [31]. Our results agree with this conclusion, and
extend it by implicating an increased relative sensitivity to
activation by nicotine as the critical factor.
The present work suggests that future analysis of rare variant
associations may depend on the development of high-throughput
methods of assessing allele function in order to clearly distinguish
the alleles with functional effects. This is due largely to three
factors. First, genes are capable of harboring alleles with opposing
effects and these opposing effects obscure each other in a
collapsing approach. For instance, in our data, the T375I variant
is protective (lower average logCPD) while the S140G variant is a
risk allele, although both have PhyloP score .2. Second, alleles
that alter protein function do not necessarily have the same
magnitude of effect and as such the variants of lesser effect can
obscure the variants of greater effect, particularly if they are of
higher frequency. This was the case for the M467V+S140G and
T375I variants. Both are protective alleles, but the M467V+
S140G variant confers only slightly lower risk than normal while
the T375I confers much less risk. Lastly, one technique to gain
power is to use only variants with putative higher prior probability
of having effects on the function of the gene product (i.e. missense
or nonsense variants, variants at evolutionarily conserved sites).
This often greatly reduces the number of variants and the number
of carriers available for association testing, thereby reducing power

and possibly obscuring associations if variants have opposing
effects. When all variants are assessed for function, each can be
used in the association test regardless of magnitude or direction of
effect.
Overall, our results indicate that incorporating functional
information into association analyses can improve power to detect
associations if relevant parameters are measured, and that
methods of assaying the functional impact of variants across the
genome will likely greatly improve our ability to understand the
genetic basis for diseases in the era of whole-exome and wholegenome sequencing. The reduction in power resulting from large
proportions of variants with little or no impact on protein function
or mixtures of protective and risk variants being included in genebased burden tests is substantial and will have to be addressed if we
hope to understand the full scope of variation impacting complex
diseases and traits. The results can also suggest possible
mechanisms for an association, in the present case indicating that
a larger relative response to low concentrations of nicotine may
reduce the risk of developing nicotine dependence.
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